Dr. Larson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5841 S. MARYLAND AVE.
M/C 2115
Chicago, IL 60637Phone+1 773-702-6783Fax+1 773-702-3002- Is this information wrong?
Summary
- Dr. Richard Larson is a hematologist-oncologist in Chicago, IL, and is affiliated with University of Chicago Medical Center. He received his medical degree from Stanford University School of Medicine and has been in practice >40 years. He specializes in hematologic oncology and is experienced in acute and chronic leukemia, chemotherapy, hematologic oncology, marrow transplantation and cellular therapy, and aplastic anemia.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 1980 - 1983- University of ChicagoResidency, Internal Medicine, 1977 - 1980
Stanford University School of MedicineClass of 1977
Certifications & Licensure
IL State Medical License 1978 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
- Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) Start of enrollment: 2009 Mar 01
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
- Join now to see all
Publications & Presentations
PubMed
- Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.Gregory W Roloff, Satyajit Kosuri, Mariam T Nawas, Adam S DuVall, Anand A Patel, Peter A Riedell, Olatoyosi Odenike, Wendy Stock, Richard A Larson, Michael R Bishop, E...> ;Haematologica. 2024 Apr 11
- Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.Rafael Madero-Marroquin, Emily Dworkin, Howard Weiner, Caner Saygin, Mariam T Nawas, Michael W Drazer, Adam S DuVall, Satyajit Kosuri, Michael J Thirman, Olatoyosi Ode...> ;Leukemia & Lymphoma. 2024 Mar 5
- Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.Johnston, H., Youshanlouei, H., Osei, C., Patel, A., DuVall, A., Wang, P., Wanjari, P., Segal, J., Venkataraman, G., Cheng, J., Gurbuxani, S., Lager, A., Fitzpatrick, ...> ;Blood Advances. 2024 Jan 9
- Join now to see all
Abstracts/Posters
- Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral TrialCl...Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH InhibitorsRichard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chr...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationJune 2017
Press Mentions
1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaDecember 2nd, 2019
Uchicago Medicine Oncologist to Receive 2019 Henry M. Stratton Medal for Hematology ResearchAugust 13th, 2019
Professional Memberships
- Member
- Member
- Member
Hospital Affiliations
University of Chicago Medical CenterChicago, Illinois
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
